West Nomogram (BSA)

The West Nomogram is a visual alignment chart developed in the 1970s to estimate Body Surface Area (BSA) from height and weight without complex calculations. BSA represents the total external surface area of the human body measured in square meters (m²), typically ranging from 0.25 m² for newborns to 1.5-2.3 m² for adults. Common BSA formulas (used instead of nomogram today): Mosteller formula (most widely used, simplest): BSA (m²) = √[(height cm × weight kg) / 3,600]. Example: 170 cm, 70 kg adult: BSA = √[(170 × 70) / 3,600] = √3.31 = 1.82 m². DuBois formula (original, 1916): BSA = 0.007184 × height^0.725 × weight^0.425. More complex but slightly more accurate for extreme body sizes. Why BSA matters in medicine: Medication dosing: Many drugs are dosed per m² BSA rather than per kg weight because physiological parameters (cardiac output, glomerular filtration rate, metabolic rate) correlate better with BSA than weight. This is especially important for: Chemotherapy: Most cytotoxic agents are dosed per m² to balance efficacy and toxicity across different body sizes. Example: Doxorubicin 60-75 mg/m² every 21 days. A 1.8 m² patient receives 108-135 mg per dose. Overdosing (using weight alone) risks severe toxicity; underdosing risks treatment failure. Immunosuppressants: Cyclosporine, tacrolimus often dosed per m² in pediatrics. Certain antibiotics: Amphotericin B, some aminoglycosides. Burn resuscitation: Fluid requirements calculated using Parkland formula: 4 mL × weight kg × % body surface burned. Accurately assessing burn BSA percentage (using Lund-Browder chart or Rule of Nines) is critical for determining fluid volumes—under-resuscitation causes shock, over-resuscitation causes pulmonary edema. Renal function normalization: Glomerular filtration rate (GFR) is reported normalized to 1.73 m² BSA (average adult BSA) to allow comparison across individuals. Formula: Normalized GFR = Measured GFR × (1.73 / patient BSA). This identifies kidney dysfunction independent of body size. Cardiac output indexing: Cardiac index (CI) = Cardiac output (L/min) / BSA (m²). Normal CI is 2.5-4.0 L/min/m². Indexing to BSA allows comparison between 50 kg and 100 kg patients. Clinical trial dosing: Many research protocols use BSA-based dosing for consistency and safety across diverse populations.

BSA formulas provide estimates within ±5-10% of directly measured BSA (via 3D body scanning or coating techniques) for most individuals, but accuracy varies by body habitus and age. Gold standard measurement (rarely used clinically): 3D body scanning: Laser or structured light scanning creates 3D body model; software calculates true surface area. Accurate within ±2-3% but requires expensive equipment ($10,000-100,000+), trained operators, 15-30 minutes. Used primarily in research. Coating method: Historical technique involving covering body with material of known area-to-mass ratio, then measuring material used. Impractical for routine use. Formula comparison and accuracy: Mosteller formula (1987): Simplest, most widely used. Accuracy ±5-8% for adults BMI 18-35. Slightly underestimates BSA for very tall/heavy individuals, overestimates for very short/light. Recommended by FDA and most institutions for ease of use. DuBois formula (1916): Original formula based on 9 subjects. Accuracy ±8-10%. Slightly more accurate than Mosteller for extreme body types but complex calculation limits use. Haycock formula (1978): BSA = 0.024265 × height^0.3964 × weight^0.5378. Derived from pediatric population. Accuracy ±5-7% for children, ±7-10% for adults. Gehan-George formula (1970): BSA = 0.0235 × height^0.42246 × weight^0.51456. Good for obese patients. Accuracy ±6-9%. Boyd formula (1935): Complex calculation involving lean body mass estimation. Rarely used due to complexity. All major formulas agree within 5-10% for typical adults (BMI 20-30, height 150-190 cm). Differences become significant at extremes. Specific population limitations: Obesity (BMI >30): Standard formulas may overestimate BSA by 10-20% because adipose tissue has lower surface area-to-volume ratio than lean tissue. A 150 kg obese person doesn't have 2× the BSA of a 75 kg lean person despite 2× weight. Implication: BSA-based chemotherapy dosing may overdose obese patients. Many oncology protocols now cap BSA at 2.0 m² or use adjusted BSA formulas, or dose-reduce by 20-25% for BMI >35. Pediatrics: Formulas derived from adult data may have ±10-15% error in infants/young children. Pediatric-specific formulas (Haycock) preferred. Premature infants have relatively higher BSA-to-weight ratio than full-term, affecting fluid/medication dosing. Amputees: Standard formulas overestimate BSA. Corrections needed: Below-knee amputation: Reduce BSA by 3-4%. Above-knee amputation: Reduce by 8-10%. Above-elbow amputation: Reduce by 5-6%. Important for chemotherapy dosing, burn assessment. Edema/ascites: Fluid accumulation increases measured weight but not true BSA, causing overestimation. Use dry weight (before fluid accumulation) when possible. Extreme heights: Very short (<140 cm) or very tall (>200 cm) adults may have ±10-15% formula error. Consider using multiple formulas and averaging. Practical implications: For routine clinical use, differences between formulas are clinically insignificant for most patients. Choose one formula (Mosteller is standard) and use consistently. For high-risk situations (chemotherapy in obese patients, pediatric critical care dosing), consider: Using obesity-adjusted BSA formulas; Capping BSA at institution-specific limits; Therapeutic drug monitoring when available; Dose adjustment based on clinical response and toxicity rather than rigid BSA calculation.

BSA-based chemotherapy dosing has been standard practice since the 1950s-1960s, but significant controversy exists regarding its accuracy and appropriateness across all patient populations. Standard BSA-based dosing: Most cytotoxic chemotherapy regimens specify dose in mg/m². Example protocols: CHOP (lymphoma): Doxorubicin 50 mg/m², Cyclophosphamide 750 mg/m² on Day 1. FOLFOX (colorectal cancer): Oxaliplatin 85 mg/m², 5-FU 400 mg/m² bolus + 2,400 mg/m² infusion. Cisplatin/Etoposide (lung cancer): Cisplatin 75 mg/m², Etoposide 100 mg/m² days 1-3. Calculation example: Patient with BSA 1.8 m² receiving CHOP: Doxorubicin dose = 50 mg/m² × 1.8 m² = 90 mg. Cyclophosphamide dose = 750 mg/m² × 1.8 m² = 1,350 mg. Rationale for BSA dosing: Historical basis: Early studies showed BSA correlated better than weight with drug clearance, toxicity, and efficacy for several agents. Physiological parameters scale with BSA: Cardiac output: 3-4 L/min/m² (BSA) versus varies widely per kg. Glomerular filtration rate: ~90-120 mL/min/1.73m² (normalized BSA). Hepatic blood flow: proportional to BSA. Practical uniformity: Allows standardized dosing across clinical trials and diverse populations. Controversies and limitations: Weak correlation with pharmacokinetics: Multiple studies show BSA explains only 20-30% of variability in drug clearance, area under curve (AUC), and toxicity for most chemotherapy agents. Other factors more important: Organ function (renal GFR, hepatic clearance). Genetic polymorphisms (e.g., UGT1A1 for irinotecan, TPMT for 6-mercaptopurine). Drug-drug interactions. Body composition (lean mass vs. fat mass). Age and comorbidities. Obesity problem: BSA continues increasing with weight, but drug clearance plateaus in obesity. Dosing obese patients by uncapped BSA often causes excessive toxicity. ASCO guidelines (2012): Recommend using actual body weight for BSA calculation (not ideal or adjusted weight) but with close monitoring. Consider dose reduction (20-25%) for BMI >40 only if initial cycle causes grade 3-4 toxicity. Many institutions cap BSA at 2.0-2.2 m² regardless of actual BSA. Example: 120 kg, 180 cm patient has BSA 2.4 m² by Mosteller, but dose is calculated using 2.0 m² cap = 17% dose reduction. Thin/cachectic patients: Low BSA (1.3-1.5 m²) may underdose chemotherapy, but these patients often have impaired organ function requiring dose reduction anyway—BSA doesn't account for this. Alternative dosing strategies under investigation: Flat dosing: Fixed dose for all adults (e.g., Carboplatin 400 mg flat dose instead of AUC-based). Studies show similar efficacy and toxicity to BSA dosing for some agents (5-FU, Carboplatin). Simpler, avoids calculation errors. Pharmacokinetic-guided dosing: Measure drug levels after first dose and adjust subsequent doses to achieve target AUC. Example: Carboplatin AUC dosing using Calvert formula: Dose (mg) = Target AUC × (GFR + 25). Targets AUC 5-7 mg·min/mL based on indication. More accurate than BSA dosing—reduces toxicity 30-50% while maintaining efficacy. Requires GFR measurement (CrCl or measured GFR). Model-based dosing: Pharmacokinetic/pharmacodynamic (PK/PD) models incorporating multiple patient factors (weight, age, organ function, genetics, prior toxicity). Individualized dosing using Bayesian algorithms. Emerging approach; requires specialized software. Therapeutic drug monitoring (TDM): Measure serum drug levels during/after infusion and adjust future doses. Available for methotrexate (target trough <0.1 μmol/L at 48-72 hours), busulfan (target AUC 900-1,500 μM·min per day). Prevents severe toxicity in patients with slow clearance. Current practice and future directions: BSA dosing remains standard for most chemotherapy despite limitations because: Established in regulatory approvals and clinical trial protocols. Simpler than alternatives (no drug level measurement, no complex calculations). Reasonable starting point for initial dose even if imperfect. Emerging consensus: BSA is reasonable initial dose estimate but should be adjusted based on: Toxicity in prior cycles (dose reduce 20-25% for grade 3-4 non-hematologic toxicity). Renal/hepatic function (many agents have organ function-based dose adjustments). Patient-specific factors (age >70, poor performance status, comorbidities warrant 20-25% empiric dose reduction). Pharmacokinetic measurements when available (carboplatin, methotrexate, busulfan). Precision oncology future: Combination of PK/PD modeling, therapeutic drug monitoring, and pharmacogenomics will replace BSA dosing with truly individualized chemotherapy dosing over next 10-20 years.

BSA is critical for pediatric medication dosing because children's physiology scales with BSA better than weight, but pediatric BSA estimation requires age-appropriate formulas and special considerations. Pediatric BSA ranges: Newborn (3.5 kg, 50 cm): BSA ~0.23-0.25 m². 1 month (4.5 kg, 55 cm): 0.26-0.28 m². 1 year (10 kg, 75 cm): 0.47-0.50 m². 5 years (18 kg, 110 cm): 0.73-0.77 m². 10 years (32 kg, 140 cm): 1.05-1.10 m². 15 years (55 kg, 165 cm): 1.55-1.65 m² (approaching adult). Preferred pediatric BSA formula: Mosteller (same as adults) is accurate for children >1 year. Haycock formula often preferred for infants <1 year: BSA = 0.024265 × height^0.3964 × weight^0.5378. More accurate for low BSA (<0.5 m²). Common pediatric BSA-based dosing: Chemotherapy: Same mg/m² dosing as adults for most agents. Example: Vincristine 1.5 mg/m² (max 2 mg) weekly. 5-year-old with BSA 0.75 m² receives 1.125 mg dose. Often capped at maximum absolute dose despite high BSA to limit toxicity—e.g., vincristine max 2 mg, regardless of BSA. Immunosuppression: Azathioprine 1-3 mg/kg or 50-100 mg/m² daily. Mycophenolate 600 mg/m² twice daily (max 1,000 mg BID). Anticoagulation: Heparin infusion: Initial 20 units/kg bolus, then 20 units/kg/hr or 500 units/m²/hr infusion. Cardiovascular drugs: Digoxin loading dose: 8-10 mcg/kg or 240 mcg/m² for age >10 years. Fluid/electrolyte management: Maintenance fluids (Holliday-Segar): 1,500 mL/m²/day (alternative to 4-2-1 rule). TPN/parenteral nutrition: Calories 1,000-1,500 kcal/m²/day. Protein 1.5-2.5 g/100 kcal or 40-60 g/m²/day. Weight-based vs. BSA-based dosing in pediatrics: Use weight-based dosing (mg/kg) when: Infant <6 months or <5 kg (BSA very small, formulas less accurate). Drug has wide therapeutic index (errors less harmful). Dosing based on volume of distribution (lipid-soluble drugs, antibiotics). Examples: Acetaminophen 10-15 mg/kg, Amoxicillin 40-50 mg/kg/day. Use BSA-based dosing (mg/m²) when: Drug has narrow therapeutic index (toxicity risk). Clearance correlates with physiologic parameters (GFR, cardiac output). Adolescents/teens approaching adult size (BSA prevents overdosing). Examples: Chemotherapy, immunosuppressants, some cardiovascular drugs. Special pediatric considerations: Premature infants: Standard formulas underestimate BSA. Premature neonates have relatively higher BSA-to-weight ratio (more surface area for heat loss, fluid loss). Modified formulas or direct measurement preferred. Dosing often uses gestational age and weight-based calculations rather than BSA. Obesity in children: Same issues as adults—BSA continues increasing but clearance plateaus. Pediatric oncology protocols increasingly cap BSA at 1.8-2.0 m² for obese adolescents or use adjusted BSA. Adolescents transitioning to adult dosing: Once BSA reaches 1.5-1.7 m² (typically age 13-16), many medications transition to adult fixed dosing rather than BSA-based. Example: Inhaled corticosteroids switch from weight/BSA dosing to standard adult doses (e.g., fluticasone 88-440 mcg BID regardless of size). Calculating BSA for dose verification: Clinical scenario: 7-year-old with acute lymphoblastic leukemia (ALL) receiving vincristine 1.5 mg/m² (max 2 mg) and doxorubicin 25 mg/m². Height 120 cm, weight 25 kg. BSA calculation (Mosteller): BSA = √[(120 × 25) / 3,600] = √0.833 = 0.91 m². Vincristine dose: 1.5 mg/m² × 0.91 m² = 1.37 mg (below 2 mg cap, so give 1.37 mg). Doxorubicin dose: 25 mg/m² × 0.91 m² = 22.75 mg (round to 23 mg). Pharmacist verification: Ensures calculated doses are reasonable. Flags if doses >10% different from expected for age/size. Safety protocols for pediatric BSA dosing: Independent double-check: Two providers (pharmacist + nurse, or two pharmacists) verify BSA calculation and dose independently. Smart pump dose limits: IV pumps programmed with age/weight-specific dose limits flag excessive doses. Chemotherapy verification: Many institutions require physician re-verification of chemotherapy doses before administration. Standardized BSA formulas: Institution selects single formula (usually Mosteller) for consistency. Height/weight accuracy: Measure height/weight on day of dosing when possible—pediatric growth can change BSA 5-10% over months. Dosing errors in pediatrics from incorrect BSA calculation can be fatal—meticulous verification protocols are essential.

BSA correlates with multiple physiological and metabolic functions, which is why it's used for normalizing clinical measurements and dosing medications. Understanding these relationships helps interpret indexed values. Cardiac output: Normal cardiac output: 4-8 L/min in adults, but varies with body size. Cardiac Index (CI): Cardiac output (L/min) / BSA (m²). Normal CI: 2.5-4.0 L/min/m² (independent of body size). Example: 70 kg, 170 cm man (BSA 1.82 m²) with cardiac output 5.5 L/min: CI = 5.5 / 1.82 = 3.0 L/min/m² (normal). 50 kg, 155 cm woman (BSA 1.45 m²) with same cardiac output 5.5 L/min: CI = 5.5 / 1.45 = 3.8 L/min/m² (normal, despite higher absolute CO due to smaller body). Clinical use: CI <2.2 L/min/m² indicates cardiogenic shock; >4.0 suggests hyperdynamic state (sepsis, hyperthyroidism). Glomerular Filtration Rate (GFR): Measured GFR: Varies with body size—larger person has more kidney mass, higher absolute GFR. Normalized GFR: Reported per 1.73 m² (average adult BSA) for standardization. Formula: Normalized GFR = Measured GFR × (1.73 / patient BSA). Example: Patient with BSA 2.1 m² and measured GFR 115 mL/min: Normalized GFR = 115 × (1.73 / 2.1) = 95 mL/min/1.73m² (normal range 90-120). Clinical use: Allows diagnosis of chronic kidney disease (GFR <60 mL/min/1.73m² = CKD stage 3) regardless of body size. Important for drug dosing—many medications require adjustment for reduced GFR. Basal Metabolic Rate (BMR) and energy expenditure: BMR per m² BSA: Approximately 900-1,000 kcal/m²/day for adults. More constant than kcal/kg (varies with obesity). Example: BSA 1.8 m²: BMR ≈ 1,800 kcal/day. BSA 2.2 m²: BMR ≈ 2,200 kcal/day. Clinical use: Estimated calorie needs for TPN, enteral nutrition: 1,000-1,500 kcal/m²/day (adults), 1,500-2,000 kcal/m²/day (children/adolescents). More accurate than simple weight-based estimates for extreme body sizes. Fluid requirements: Maintenance fluid (Holliday-Segar): 1,500 mL/m²/day (alternative to 4-2-1 rule). Example: 25 kg child with BSA 0.85 m²: Maintenance = 1,500 × 0.85 = 1,275 mL/day (~53 mL/hr). Insensible losses: Approximately 400-600 mL/m²/day through skin and respiration. Higher with fever (12-13% increase per °C elevation). Blood volume: Estimated blood volume: ~75 mL/kg in adults, but varies with body composition. BSA-based estimate: ~2,500 mL/m² (more constant across different body types). Example: BSA 1.8 m²: Blood volume ≈ 4,500 mL. BSA 2.2 m²: Blood volume ≈ 5,500 mL. Clinical use: Estimating blood volume for transfusion, calculating allowable blood loss during surgery, determining blood product dosing. Body temperature regulation: Heat loss is proportional to surface area (BSA), while heat production is proportional to mass (weight). Infants and small children have high BSA-to-weight ratio (0.05-0.10 m²/kg versus 0.02-0.03 m²/kg in adults) → lose heat rapidly → require warmer environments. Example: 5 kg infant (BSA 0.27 m²): BSA/weight = 0.054 m²/kg. 70 kg adult (BSA 1.82 m²): BSA/weight = 0.026 m²/kg. Infant has 2× higher heat loss per kg, explaining hypothermia risk. Clinical use: Neonatal/pediatric thermoregulation (warmer isolettes, radiant warmers). Calculating fluid requirements during fever (increase by 10-12% per °C). Drug clearance: Hepatic clearance: Hepatic blood flow (~1,500 mL/min/1.73m²) scales with BSA. Drugs with high hepatic extraction (propranolol, morphine, lidocaine) have clearance proportional to BSA. Renal clearance: GFR scales with BSA (as above). Renally cleared drugs (aminoglycosides, vancomycin, methotrexate) have clearance proportional to BSA. Limitation: BSA explains only 20-40% of inter-individual variability in clearance—other factors (genetics, organ function, age) often more important. Oxygen consumption (VO₂): Resting VO₂: ~120-140 mL/min/m² in adults. Example: BSA 1.8 m²: VO₂ ≈ 225 mL/min. BSA 2.2 m²: VO₂ ≈ 275 mL/min. Clinical use: Calculating metabolic rate in ICU patients (indirect calorimetry). Estimating oxygen requirements during mechanical ventilation. Practical clinical applications: When to use BSA-indexed values: Comparing measurements across different body sizes (e.g., cardiac output in 50 kg vs. 100 kg patient). Adjusting drug doses for physiologic parameters (chemotherapy, immunosuppression). Normalizing laboratory values (GFR, cardiac index). When BSA indexing is less helpful: Obesity (BSA continues increasing but physiology plateaus). Extreme ages (premature infants, elderly with sarcopenia). Conditions altering body composition (malnutrition, edema, amputation). In these cases, consider lean body mass or ideal body weight adjustments rather than total BSA.

BSA is essential for burn management in two ways: (1) assessing the percentage of total body surface area burned (TBSA%) to determine burn severity, and (2) calculating fluid resuscitation requirements using the Parkland formula. Assessing burn TBSA% (percent of body surface burned): Rule of Nines (adults): Divides body into regions, each ~9% or multiple of 9%: Head/neck: 9%. Each arm: 9% (total 18% both arms). Anterior trunk: 18% (chest + abdomen). Posterior trunk: 18% (back). Each leg: 18% (total 36% both legs). Perineum/genitals: 1%. Example: Burn involving entire right arm, anterior trunk, and anterior right leg: Right arm (9%) + Anterior trunk (18%) + Anterior right leg (9%, half of 18%) = 36% TBSA burn. Lund-Browder Chart (more accurate, especially pediatrics): Accounts for age-related body proportion differences. Provides detailed body diagram with age-adjusted percentages. Example: In infant, head is 18-19% (versus 9% in adult); legs are 14% each (versus 18% in adult). Preferred for children and precise assessment. Palm method (small burns): Patient's palm (including fingers) = ~1% TBSA. Useful for estimating small scattered burns. Example: 8 palm-sized burns = ~8% TBSA. Burn severity classification by TBSA%: Minor burn: <10% TBSA (15% in children). Outpatient management often appropriate. Moderate burn: 10-20% TBSA partial-thickness. Hospital admission required. Major burn: >20% TBSA partial-thickness, >10% full-thickness, or burns involving face/hands/feet/genitalia/major joints. Burn center referral indicated. Massive burn: >40-50% TBSA. High mortality risk (50-90% depending on age/comorbidities); requires intensive care, aggressive fluid resuscitation. Fluid resuscitation using Parkland Formula: Parkland Formula: Total fluid (first 24 hours) = 4 mL × body weight (kg) × % TBSA burned. Uses Lactated Ringer's solution (crystalloid). Administration schedule: Give 50% of total in first 8 hours (from time of burn, not from arrival). Give remaining 50% over next 16 hours. Example calculation: 70 kg man with 30% TBSA flame burn at 6:00 PM. Total 24-hour fluid: 4 mL × 70 kg × 30% = 8,400 mL Lactated Ringer's. First 8 hours (until 2:00 AM): 8,400 × 0.5 = 4,200 mL = 525 mL/hr. Next 16 hours (2:00 AM to 6:00 PM): 8,400 × 0.5 = 4,200 mL = 263 mL/hr. If patient arrives 2 hours after burn (8:00 PM): First 8-hour period already 2 hours elapsed, so 4,200 mL must be given over remaining 6 hours = 700 mL/hr to catch up. Monitoring and adjusting resuscitation: Parkland formula is starting estimate—actual fluid needs vary ±50% based on burn depth, inhalation injury, delay to treatment. Target urine output: Adults: 0.5-1.0 mL/kg/hr (35-70 mL/hr for 70 kg patient). Children: 1.0 mL/kg/hr. Adjust infusion rate based on urine output: If urine output <0.5 mL/kg/hr → increase IVF rate 20-30%. If urine output >1.0 mL/kg/hr consistently → decrease IVF rate 20-30% (risk of fluid overload). Other monitoring: Blood pressure, heart rate, mental status, lactate (should decrease with adequate resuscitation), hemoglobin/hematocrit (hemoconcentration suggests under-resuscitation). Complications of inadequate/excessive resuscitation: Under-resuscitation: Hypovolemic shock → acute kidney injury (burn shock is most common cause of early mortality). Oliguria, rising creatinine, metabolic acidosis, hypotension. Over-resuscitation: Fluid overload → abdominal compartment syndrome (increased intra-abdominal pressure >20 mmHg from bowel edema → organ dysfunction), pulmonary edema, compartment syndrome in burned extremities (worsens by edema), delayed wound healing. Modified Parkland/alternative formulas: Some burn centers use 2-3 mL/kg/%TBSA instead of 4 mL/kg/%TBSA to reduce over-resuscitation. Colloid addition: Some protocols add albumin after first 8-24 hours if large volumes of crystalloid required (improves oncotic pressure, may reduce total volume needed). Hypertonic saline: Experimental; may reduce fluid volume but risks hypernatremia. Pediatric differences: Children have higher BSA-to-weight ratio → greater evaporative losses. Parkland formula for children: Same 4 mL/kg/%TBSA plus maintenance fluids (4-2-1 rule or 1,500 mL/m²/day). Example: 20 kg child, 25% TBSA burn: Parkland: 4 × 20 × 25 = 2,000 mL. Maintenance (4-2-1): (4 × 10) + (2 × 10) = 60 mL/hr × 24 hr = 1,440 mL. Total first 24 hours: 3,440 mL (versus 2,000 mL for adult formula alone). Key principles: Burn TBSA% determines if patient needs IV resuscitation (generally required for >10-15% TBSA adults, >10% children). Parkland formula provides initial estimate; tailor to patient response (urine output, vital signs, lactate). Early aggressive resuscitation in first 8-24 hours prevents burn shock and acute kidney injury—leading cause of early mortality. Avoid over-resuscitation after first 24 hours—causes complications (compartment syndrome, ARDS, delayed healing).